← All trials
NCT03087773
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2017
- Primary completion
- Nov 2, 2019
- Completion date
- Apr 2, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 476
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Medical University of GrazLead sponsor
- Johannes Kepler UniversityCollaborator
- Medical University of GrazOverall official - principal investigator
- Medical University of GrazStudy director
- United Arab Emirates UniversityCollaborator
- Paracelsus Medical UniversityCollaborator
- University of ViennaCollaborator
- Landeskrankenhaus FeldkirchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.